523 related articles for article (PubMed ID: 16990111)
1. Cladribine in hairy cell leukemia.
Belani R; Saven A
Hematol Oncol Clin North Am; 2006 Oct; 20(5):1109-23. PubMed ID: 16990111
[TBL] [Abstract][Full Text] [Related]
2. Rituximab as treatment for minimal residual disease in hairy cell leukaemia.
Cervetti G; Galimberti S; Andreazzoli F; Fazzi R; Cecconi N; Caracciolo F; Petrini M
Eur J Haematol; 2004 Dec; 73(6):412-7. PubMed ID: 15522063
[TBL] [Abstract][Full Text] [Related]
3. [Hairy cell leukemia. An alternative method for the detection of minimal residual disease using flow cytometry].
Bengio R; Narbaitz M; Palacios F; Scolnik M; Sarmiento M
Medicina (B Aires); 2000; 60 Suppl 2():71-6. PubMed ID: 11188936
[TBL] [Abstract][Full Text] [Related]
4. Minimal residual disease in hairy-cell leukemia after treatment with 2-chlorodeoxyadenosine.
Konwalinka G; Schirmer M; Hilbe W; Fend F; Geisen F; Knoblechner A; Petzer A; Thaler J
Blood Cells Mol Dis; 1995; 21(2):142-51. PubMed ID: 8846043
[TBL] [Abstract][Full Text] [Related]
5. A single course of 2-chloro-deoxyadenosine does not eradicate leukemic cells in hairy cell leukemia patients in complete remission.
Filleul B; Delannoy A; Ferrant A; Zenebergh A; Van Daele S; Bosly A; Doyen C; Mineur P; Glorieux P; Driesschaert P
Leukemia; 1994 Jul; 8(7):1153-6. PubMed ID: 7913513
[TBL] [Abstract][Full Text] [Related]
6. The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia.
Else M; Osuji N; Forconi F; Dearden C; Del Giudice I; Matutes E; Wotherspoon A; Lauria F; Catovsky D
Cancer; 2007 Nov; 110(10):2240-7. PubMed ID: 17886250
[TBL] [Abstract][Full Text] [Related]
7. [Hairy cell leukemia--a potentially curable malignancy. Selected aspects of purine analog therapy].
Rucińska M; Machaczka M; Załuska A; Skotnicki AB
Przegl Lek; 1998; 55(7-8):400-6. PubMed ID: 10021885
[TBL] [Abstract][Full Text] [Related]
8. [Monitoring minimal residual disease in patients with hairy cell leukemia in complete remission after treatment with 2-chlorodioxyadenosine].
Zák P; Chrobák L; Dĕdic K; Podzimek K
Vnitr Lek; 2000 Oct; 46(10):697-703. PubMed ID: 11344629
[TBL] [Abstract][Full Text] [Related]
9. Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2-deoxycoformycin and prediction of early relapse.
Tallman MS; Hakimian D; Kopecky KJ; Wheaton S; Wollins E; Foucar K; Cassileth PA; Habermann T; Grever M; Rowe JM; Peterson LC
Clin Cancer Res; 1999 Jul; 5(7):1665-70. PubMed ID: 10430066
[TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis.
Else M; Dearden CE; Matutes E; Garcia-Talavera J; Rohatiner AZ; Johnson SA; O'Connor NT; Haynes A; Osuji N; Forconi F; Lauria F; Catovsky D
Br J Haematol; 2009 Jun; 145(6):733-40. PubMed ID: 19344416
[TBL] [Abstract][Full Text] [Related]
11. Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years.
Else M; Ruchlemer R; Osuji N; Del Giudice I; Matutes E; Woodman A; Wotherspoon A; Swansbury J; Dearden C; Catovsky D
Cancer; 2005 Dec; 104(11):2442-8. PubMed ID: 16245328
[TBL] [Abstract][Full Text] [Related]
12. Flow cytometry of peripheral blood and bone marrow cells from patients with hairy cell leukemia: phenotype of hairy cells, lymphocyte subsets and detection of minimal residual disease after treatment.
Babuŝíková O; Tomová A; Kusenda J; Gyárfás J
Neoplasma; 2001; 48(5):350-7. PubMed ID: 11845978
[TBL] [Abstract][Full Text] [Related]
13. Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine).
Füreder W; Weltermann A; Chott A; Gisslinger H; Valent P; Jäger U; Geissler K; Lechner K
Wien Klin Wochenschr; 1999 Dec; 111(24):1027-30. PubMed ID: 10677889
[TBL] [Abstract][Full Text] [Related]
14. Hairy cell leukemia: towards a curative strategy.
Gidron A; Tallman MS
Hematol Oncol Clin North Am; 2006 Oct; 20(5):1153-62. PubMed ID: 16990114
[TBL] [Abstract][Full Text] [Related]
15. Implications of minimal residual disease in hairy cell leukemia after cladribine using immunohistochemistry and immunophenotyping.
Tallman MS
Leuk Lymphoma; 2011 Jun; 52 Suppl 2():65-8. PubMed ID: 21463116
[TBL] [Abstract][Full Text] [Related]
16. [Hairy cell leukemia treated with cladribine].
Ghanima W; Heldal D; Tjønnfjord GE
Tidsskr Nor Laegeforen; 2002 Apr; 122(11):1094-7. PubMed ID: 12043051
[TBL] [Abstract][Full Text] [Related]
17. Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell Leukemia.
Chihara D; Arons E; Stetler-Stevenson M; Yuan CM; Wang HW; Zhou H; Raffeld M; Xi L; Steinberg SM; Feurtado J; James L; Wilson W; Braylan RC; Calvo KR; Maric I; Dulau-Florea A; Kreitman RJ
J Clin Oncol; 2020 May; 38(14):1527-1538. PubMed ID: 32109194
[TBL] [Abstract][Full Text] [Related]
18. Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma.
Andersen NS; Pedersen LB; Laurell A; Elonen E; Kolstad A; Boesen AM; Pedersen LM; Lauritzsen GF; Ekanger R; Nilsson-Ehle H; Nordström M; Fredén S; Jerkeman M; Eriksson M; Väärt J; Malmer B; Geisler CH
J Clin Oncol; 2009 Sep; 27(26):4365-70. PubMed ID: 19652064
[TBL] [Abstract][Full Text] [Related]
19. Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia.
Del Poeta G; Del Principe MI; Buccisano F; Maurillo L; Capelli G; Luciano F; Perrotti AP; Degan M; Venditti A; de Fabritiis P; Gattei V; Amadori S
Cancer; 2008 Jan; 112(1):119-28. PubMed ID: 17999417
[TBL] [Abstract][Full Text] [Related]
20. [Successful use of cladribine in the treatment of an elderly woman with typical hairy cell leukemia].
Terasaki Y; Okumura H; Hirose A; Ishiura Y; Yokawa S; Saito K; Nakao S
Gan To Kagaku Ryoho; 2007 Nov; 34(11):1885-8. PubMed ID: 18030031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
